Oncolytics Biotech Reports Durability and Survival Data in Anal Cancer
The company said GOBLET Cohort 4 showed an approximately 15-month median duration of response, exceeding historical results for approved second-line checkpoint inhibitor monotherapy. It also said all responding patients survived longer than one year.